SI9720015A - Postopek za preprečevanje staranja kože zaradi vpliva svetlobe - Google Patents
Postopek za preprečevanje staranja kože zaradi vpliva svetlobe Download PDFInfo
- Publication number
- SI9720015A SI9720015A SI9720015A SI9720015A SI9720015A SI 9720015 A SI9720015 A SI 9720015A SI 9720015 A SI9720015 A SI 9720015A SI 9720015 A SI9720015 A SI 9720015A SI 9720015 A SI9720015 A SI 9720015A
- Authority
- SI
- Slovenia
- Prior art keywords
- skin
- mmp
- light
- influence
- uvb
- Prior art date
Links
- 206010051246 Photodermatosis Diseases 0.000 title abstract 2
- 230000008845 photoaging Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 4
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 29
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract 2
- 230000032683 aging Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 26
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 14
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 239000011604 retinal Substances 0.000 claims description 7
- 229930002330 retinoic acid Natural products 0.000 claims description 7
- 229960003471 retinol Drugs 0.000 claims description 7
- 235000020944 retinol Nutrition 0.000 claims description 7
- 239000011607 retinol Substances 0.000 claims description 7
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 7
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 6
- 229960005280 isotretinoin Drugs 0.000 claims description 6
- 230000002207 retinal effect Effects 0.000 claims description 6
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims description 5
- 229950008959 marimastat Drugs 0.000 claims description 5
- 239000003558 transferase inhibitor Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 108010005721 B 581 Proteins 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- NCYCYZXNIZJOKI-HWCYFHEPSA-N 13-cis-retinal Chemical compound O=C/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HWCYFHEPSA-N 0.000 claims 5
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 5
- 229940123468 Transferase inhibitor Drugs 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 5
- 102000020233 phosphotransferase Human genes 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 230000006698 induction Effects 0.000 description 23
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 22
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 22
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 18
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229940124761 MMP inhibitor Drugs 0.000 description 10
- 238000011282 treatment Methods 0.000 description 7
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 6
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102100030416 Stromelysin-1 Human genes 0.000 description 6
- 101710108790 Stromelysin-1 Proteins 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000000475 sunscreen effect Effects 0.000 description 5
- 239000000516 sunscreening agent Substances 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000011068 Cdc42 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100028848 Stromelysin-2 Human genes 0.000 description 2
- 101710108792 Stromelysin-2 Proteins 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000039539 Fos family Human genes 0.000 description 1
- 108091067362 Fos family Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 101150096607 Fosl2 gene Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013404 Geranyltranstransferase Human genes 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 108040006417 JUN kinase kinase activity proteins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 208000032821 Macular pigmentation Diseases 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Percussion Or Vibration Massage (AREA)
- Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
Abstract
Staranje nepoškodovane kože zaradi vpliva svetlobe zaradi izpostavljanja UVB sevanju preprečujemo z dajanjem sredstva, ki inhibira vsaj enega od (1) aktivnost z UVB sevanjem inducibilnih MMP v koži, (2) enega ali obeh transkripcijskih faktorjev AP-1 in NF-KB ali (3) vsaj enega od GTP vezavnih proteinov ali kinaz, vpletenih v aktivacijo in/ali proizvodnjo jun ali fos proteinov, ki obsegajo AP-1; in inhibitor lokalno dajemo na kožo pred takim izpostavljanjem.ŕ
Description
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Postopek za preprečevanje staranja kože zaradi vpliva svetlobe
Tehnično področje
Predloženi izum je s področja zaščite proti vplivu svetlobe. Natančneje se nanaša na postopek za preprečevanje staranja nepoškodovane kože zaradi vpliva svetlobe ob uporabi inhibitorjev proizvodnje in/ali aktivnosti matrične metaloproteinaze (MMP).
Ozadje
Staranje zaradi vpliva svetlobe je izraz, ki se uporablja za opisovanje sprememb videza in funkcije kože kot rezultat ponovljenega izpostavljanja sončni svetlobi. Ultravijolična (UV) komponenta sončne svetlobe, zlasti srednja UV (imenovana UVB, valovna dolžina 290-320 nm), je glavni povzročitelj staranja zaradi vpliva svetlobe. Obseg izpostavljanja UVB, kije potreben, da povzroči staranje zaradi vpliva svetlobe, trenutno ni znan. Ponovljeno izpostavljanje UVB pri nivojih, ki povzročijo rdečino in porjavitev, pa je običajno povezano s staranjem zaradi vpliva svetlobe. Klinično je staranje zaradi vpliva svetlobe okarakterizirano s hrapavastjo, gubavostjo, marogasto pigmentacijo, nezdravo barvo kože, ohlapnostjo, teleangiektazijo, pegami, purpuro in lahko ranitvijo, atrofijo, fibrotičnimi depigmentiranimi površinami in končno predmalignimi in malignimi neoplazmami. Staranje zaradi vpliva svetlobe se običajno pojavi na koži, kije stalno izpostavljena sončni svetlobi, kot je obraz, ušesa, pleša na lasišču, vrat m roke.
Na razpolago so postopki za preprečevanje staranja nepostarane kože zaradi vpliva svetlobe in za zdravljenje kože, že postarane zaradi vpliva svetlobe. Sredstva za zaščito pred soncem se običajno uporabljajo za preprečevanje staranja površin kože zaradi vpliva svetlobe, ki so stalno izpostavljene sončni svetlobi. Sredstva za zaščito pred soncem so lokalni pripravki, ki absorbirajo, odbijajo ali razpršijo UV. Nekatera so na osnovi opačnega materiala v delcih, kot so cinkov oksid, titanov oksid, gline m železov(III) klorid. Ker so taki pripravki vidni in okluzivni, smatrajo mnogi ljudje te opačne pripravke kot kozmetično nesprejemljive. Druga sredstva za zaščito pred soncem vsebujejo kemikalije, kot p-aminobenzojsko kislino (PABA), oksibenzon, dioksibenzon, etilheksil-metoksicinamid in butilmetoksidibenzoilmetan, ki niso opačne in so brezbarvne, ker ne absorbirajo svetlobe vidnih valovnih dolžin. Čeprav so lahko ta ne-opačna sredstva za zaščito pred soncem kozmetično bolj sprejemljiva, imajo še vedno relativno kratek rok trajanja m so podvržena temu, da se odstranijo z umivanjem ali znojenjem. Poleg tega vsa sredstva za zaščito pred soncem zmanjšajo proizvodnjo vitamina D.
Rieger, M.M. Cosmetics and Toiletnes (1993) 108:43-56, ocenjuje vlogo reaktivnih kisikovih vrst (ROS) pri staranju kože, povzročenem z UV. V tem članku je navedeno, da lahko lokalna aplikacija znanih antioksidantov na kožo zmanjša prisotnost ROS v koži in tako zmanjša poškodovanje zaradi vpliva svetlobe.
Za zadrževanje učinkov staranja kože, poškodovane zaradi sonca, zaradi vpliva svetlobe so uporabili retinoide. V US 4,877,805 je opisano zdravljenje zaradi vpliva svetlobe postarane kože kot intervencijska terapija za upočasnenje procesa staranja zaradi vpliva svetlobe. V patentu je navedeno, da nima smisla začeti s takim zdravljenjem, dokler se ne začnejo pojavljati učinki staranja. V tem pogledu sedanji prijavitelji ne poznajo stanja tehnike, pri katerem bi predlagali uporabo retinoidov za preprečevanje staranja nepoškodovane kože zaradi vpliva svetlobe.
MMP so družina encimov, ki igrajo glavno vlogo pri fiziološkem in patološkem uničenju veznega tkiva. Identificirali so nad 10 Članov družine. Označeni so številčno (MMP-1, MMP-2 itd.) kot tudi z generičnim imenom. Zdi se, da imajo skupnih več strukturnih m funkcionalnih lastnosti, razlikujejo pa se v specifičnostih svojih tkivnih substratov. Vključujejo intersticijsko kolagenazo (MMP-1) in PMN-kolagenazo MMP-8), ki razgradita kolagenske tipe I, II, III, VII, VIII, IX in želatino; 72kDa (MMP-2) in 92kDa (MMP-9) tip IV kolagenaze/želatinaze, ki razgradijo kolagenske tipe IV, V, VII, X, XI, želatino, elastin in fibronektin; stromelizin-1 (MMP-3), stromelizin-2 (MMP-10) m stromelizin-3 (MMP-11), ki razgradijo fibronektin, PG jedmi protein, kolagenske tipe IV, V, IX in X, laminin in elastin; PUMP-1 (MMP-7), ki razgradi kolagenski tip IV, želatino, laminin, fibronektin in PG jedmi protein; in metaloelastazo (MMP-12), ki razgradi elastin in fibronektin.
Ekspresijo MMP genov inducirajo transkripcij ski faktorji AP-1 in NF-KB. Angel, P. et al., Celi (1987) 49:729-739, in Sato, H m Seiki, M. Oncogene (1993) 8:395-405. AP-1 in NF-KB aktivnosti mediirajo citokini (npr. interlevkini IL-1, IL-6 in TNFa), rastni faktorji (TGFa, bFGF) in okolišne obremenitve, kot so oksidanti, vročina in UVsevanje. AP-1 indukcijo in proizvodnjo jun proteinov (C-jun, jun-B in jun-D) in fos proteinov (C-fos, fos-B, fra-1 in fra-2), ki dopolnijo AP-1, mediira gostitelj molekul (npr. RAC, CDC42, MEKK, JNKK, JNK, RAS, RAF, MEK m ERK). Znano je, da se AP-1 in NF-KB aktivirata v celicah sesalcev, ki so izpostavljene UV svetlobi. Devary, Y., et al. Science (1993) 261:1442-1445. Wlaschek, M. et al., Photochemistry and Photobiology (1994) 59(5):550-556, tudi poroča, daje posledica UVA obsevanja fibroblastov IL-1 in IL-6-mediirana indukcija MMP-1 in da lahko taka indukcija prispeva k izgubi kolagena pri staranju zaradi vpliva svetlobe.
Inhibitorji MMP ali transkripcijski faktorji, ki prizadenejo njihovo ekspresijo, so tudi znani. Hill, P.A. et al., Biochem J (1995) 308; 167-175, opisuje dva MMP inhibitorja, CT1166 in RO31-7467. Gowravaram, M.R. et al., J Med Chem (1995) 38:2570-2581, opisuje razvoj vrste hidroksamatov, ki inhibirajo MMP, in omenja tiole, fosfonate, fosfmate, fosforamidate in N-karboksi alkile kot znane MMP inhibitorje. V tem članku je navedeno, da MMP inhibitorji vključujejo del, ki kelira cink in peptidni fragment, ki veže podvrsto specifičnostnih žepov MMP. Hodgson, J., Biotechnology (1995) 13:554-557, ocenjuje klinični status več MMP inhibitorjev, vključno kot so galardin, batimastat in marimastat. Drugi MMP inhibitorji vključujejo butandiamid (Conway, J.G. et al., J Exp Med (1995) 182:449-457), TIMP (Mauch C., et al., Arch Dermatol Res (1994) 287:107-114) in retinoide (Fanjul, A. et al., Nature (1994)
372:107-111; Nicholson, R.C. et al., EMBO Journal (1990) 9(13) 4443-4454; in Bailly, C. et.al., J Investig Derm (1990) 94(1):47-51).
Opis izuma
Predloženi izum temelji na odkritju prijaviteljev, da izpostavljenost UVB hitro dvigne AP-1 in NF-KB v izpostavljeni koži in vodi do MMP indukcije. Povišani nivoji MMP, ki so posledica izpostavljanja UVB, delujejo tako, da razgradijo proteine veznega tkiva v koži. Posledica take poškodbe, če ni popolnoma ozdravljena, so sončne brazgotine, ki se nabirajo med ponovljenim izpostavljanjem UVB in tudi povzročijo staranje zaradi vpliva svetlobe.
Torej prijavitelji preprečujejo staranje nepoškodovane človeške kože zaradi vpliva svetlobe zaradi izpostavljanja kože UVB z dajanjem inhibitorja UVB-inducibilnega MMP človeku pred izpostavljanjem v količim, kije zadostna, da inhibira indukcijo in/ali aktivnosti UVB-inducibilmh MMP. Presenetljivo se to zgodi pri UVB dozah pod tistimi, ki povzročijo rdečino, kot tudi pri tistih, ki povzročijo rdečino.
Drugi vidik predloženega izuma je uporaba inhibitorja indukcije ali aktivnosti UVBinducibilnega MMP za izdelavo zdravila za preprečevanje staranja nepoškodovane kože zaradi vpliva svetlobe zaradi ponovljenega izpostavljanja UVB.
Kratek opis risb
V risbah:
je sl. 1 shema, ki prikazuje poti, po katerih UVB inducira MMP proizvodnjo.
Sl. 2a-d, 3a-b, 4a-d in 5a-e so grafi testnih rezultatov, opisanih v spodnjih primerih.
Načini za izvedbo izuma
Predloženi izum se uporablja za lnhibiranje (t.j. zmanjšanje ali preprečevanje) staranja nepoškodovane človeške kože zaradi vpliva svetlobe, t.j. kože, ki ne kaže učinkov staranja zaradi vpliva svetlobe. Zdravljenje v skladu s predloženim izumom je treba torej izvajati na koži, kot je koža glave, vratu in rok, ki je v tipičnem vsakdanjem življenju stalno izpostavljena sončni svetlobi, preden taka koža pokaže očitne znake staranja zaradi vpliva svetlobe. Ker lahko ponovljeno izpostavljanje dozam UVB, ki so pod tistimi, ki povzročijo rdečino, vodi do staranja zaradi vpliva svetlobe, je treba izvajati izum na koži, kije podvržena takemu izpostavljanju nizki dozi. V tem oziru povzročajo UVB doze v območju 30-50 mJ/cm kože rdečino pri večini svetlopoltih ljudi. Torej bomo z izumom preprečili staranje kože, podvržene dozam pod tem območjem (tipično nad okoli 5 mJ/cm2, kar je ekvivalentno nekaj minutam izpostavljanja sončm svetlobi).
Staranje zaradi vpliva svetlobe preprečimo ali inhibiramo v smislu izuma z inhibiranjem UVB-inducirane razgradnje kožne ekstracelulame matrice z MMP. To dosežemo z dajanjem MMP inhibitorja na kožo, ki naj bi jo izpostavljali sončni svetlobi. V tem oziru izraz MMP inhibitor pomeni tista sredstva, ki direktno ali indirektno inhibirajo (t.j. znatno zmanjšajo ali odstranijo) ekspresijo UVBmducibilnih MMP v taki koži ali inhibirajo encimatsko aktivnost takih MMP. Z “indirektno inhibicijo” je mišljena interakcija z vsakim ali z obema od transkripcijskih faktorjev AP-1 in NF-KB in/ali eno ali več od molekul, ki so vpletene v vse tri kinazne kaskade, katerih posledica je jun in fos proteinska indukcija v koži na način, ki zmanjša ali odstrani ekspresijo UVB-inducibilmh MMP.
Sl. I shematsko prikazuje poti ekspresije UVB-inducibilnih MMP. Kot je prikazano na sl. 1, UVB-izpostavljanje ustvari reaktivne kisikove intermediate (ROI), ki stimulirajo AP-1 in NF-KB aktivnost, kar po dragi strani inducira citokine in rastne faktorje. Interakcijo teh citokinov in faktorjev z njihovimi receptorji sprožijo majhni GTP vezavni proteini RAC/CDC42 in RAS. Ti proteini aktivirajo vse tli kinazne kaskade, ki so bistvene za proizvodnjo jun in fos proteinov, ki dopolnijo AP-1. AP-1 inducira ekspresijo določenih MMP. Sredstva, ki preprečujejo staranje zaradi vpliva svetlobe, lahko vplivajo na MMP, transkripcijske faktorje AP-1 in NF-KB in/ali eno ali več od molekul, vpletenih v vse tri kinazne kaskade, prikazane na sl. 1. Aspirin in E5510 (opisano v Fujimori, T., et al., Jpn J Pharmacol (1991) 55(1):81-91) inhibirata NF-KB aktivacijo. Famezil transferazni inhibitorji, kot B-581 (opisano v Garcia A.M., et al., J Biol Chem (1993) 268(25):18415-18), ΒΖΑ-5Β (opisano v Dalton M.B. et al., Cancer Res (1995) 55(15):3295-3304), famezil acetat in (a-hidroksifarnezil)fosforjeva kislina delujejo na RAS in inhibirajo aktivacijo ERK kaskade; medtem ko geranil geraniltransferazni inhibitorji in lizofilin inhibirajo aktivacijo JNK kaskade. Spojine, kot SB202190 (opisano v Lee, J.C., et al., Nature (1994) 372:739-746), in PD98059 (opisano v Dudley, D.T., et al., PNAS (USA) (1995) 92:7686-7689), inhibirajo specifične kinaze v kaskadah. Retinoidi, kot tisti, opisani v US 4,877,805, in disociirajoči retinoidi, ki so specifični za AP-1 antagonizem, kot tisti, opisani v Fanjul, et al., (Nature (1994) 372:104-110), glukokortikoidi in vitamin D3 ciljajo AP-1.
Drugi retinoidi poleg retinola vključujejo naravne in sintetične analoge vitamina A (retinol), vitamin A aldehida (retinal), vitamin A kisline (retinojska kislina, vključno all-trans in 13-cis retinojska kislina) in druge, kot je opisano v EP 379367 A2. Končno lahko MMP inhibiramo z BB2284 (opisano v Gearing, A.J.H. et al., Nature (1994) 370-555-557), GI129471 (opisano v McGeehan G.M., et al., Nature (1994) 370:558561), TIMPS, galardinom, batimastatom in marimastatom in hidroksamati in drugimi znanimi inhibitorji.
Enega ali več od teh MMP inhibitorjev prednostno dajemo lokalno na kožo, ki naj bi jo izpostavljali sončni svetlobi. Za tako dajanje jih bomo običajno formulirali kot kreme, gele, mazila, spreje ali losione. Za formuliranje inhibitorja (inhibitorjev) lahko uporabimo običajne farmakološko in kozmetično sprejemljive inhibitorje. Primeri takih nosilcev so opisani v US 4,877,805 in EP 0586106 Al. Kot je navedeno, je lahko eden ali več inhibitorjev prisotnih v dani formulaciji. Npr. lahko uporabimo kombinacijo inhibitorjev, ki učinkujejo na dve ali več različnih molekul, vpletenih v povzročitev MMP razgradnje kože. Formulacije lahko tudi vsebujejo dodatke, kot so mehčala, povečevalci kožne permeacije, pigmenti in parfumi. Poleg tega lahko formulacija vsebuje sestavine, kot so absorbentski delci (npr. polimerni biseri), ki zagotovijo zadrževano sproščanje inhibitorjev na kožo. Masna koncentracija inhibitorja (inhibitorjev) v formulaciji bo običajno 0,01% do 10%, bolj običajno 0,1% do 1%. Običajno bomo nanesli na cm kože okoli 50 mg formulacije.
Inhibitorje prednostno nanesemo na nepoškodovano kožo pred izpostavljanjem sončni svetlobi. Režim nanašanja (t.j. dnevno, tedensko, itd.) bo v prvi vrsti odvsen od dolgoživosti (npr. metabolizma, razpolovnega časa v koži) inhibitorja (inhibitorjev) in molekulskih tarč njihovega učinka. Nanj lahko tudi vpliva kopanje, znojenje in obseg izpostavljanja sončni svetlobi. Običajno jih bomo nanašali dnevno.
Izum nadalje ilustrirajo naslednji primeri. Ti primeri niso mišljeni kot kakršnokoli omejevanje izuma.
PRIMERI
Določitev molekulske baze UVB-induciranega staranja zaradi vpliva svetlobe Indukcija MMP z visoko UVB dozo
Časovni potek sprememb v MMP-1, MMP-3, MMP-9 in MMP-2 mRNA, proteinskih in encimatskih aktivnostnih nivojih po UVB izpostavljanju smo določili, kot sledi.
Osebki so bili odrasli belci (približno enako število moških in žensk) s svetlo do rahlo pigmentacijo. UVB dozo, potrebno za povzročitev komaj zaznavnega pordečenja kože (minimalna eritemska doza ali “MED”), za vsak osebek smo določili 24 ur po obsevanju. Ena (1) MED za vse osebke je bila v območju od 30-50 mJ/cm . Zadnjice osebkov smo obsevali z 2 MED UVB z Ultralite Panelite svetilko, ki je vsebovala štiri F36T12 ERE-VHO UVB cevi. Obsevalno intenziteto smo kontrolirali z IL443 fototerapijskim radiometrom in SED240/UVB/W fotodetektorjem. UVB produkcija, merjena 48 cm od vira, je bila 0,5 mW/cm . Za vsak osebek smo kožo odstranili s keratomom s štirih mest (eno neobsevano, tri obsevana) pri 8, 16, 24, 48 in 72 urah po obsevanju. Tkivo smo hitro zamrznili ter totalno RNA izolirali in analizirali z
Northern blot-om, kot je opisano v Fisher, G.J. et al., J Invest Dermatol (1991) 96:699-707. Intenzitete trakov smo kvantificirali s Phosphorlmager-jem. Vrednosti za MMP transkripte smo normalizirali na tiste za kontrolni gen 36B4. Rezultati teh testov so prikazani na sl. 2a (MMP-1), 2b (MMP-3), 2c (MMP-9) in 2d (MMP-2). Rezultati so povprečja ± SEM (n=6 za 8, 16, 48 in 72 ur m n=17 za kontrolo brez UVB in 24 ur) in so predstavljeni kot kratno povečanje normaliziranih vrednosti glede na neobsevano kožo. Trakovi, prikazani na slikah, so kompoziti več posameznikov.
Kot je prikazano na sl. 2a-d, je bila indukcija MMP-1, MMP-3 in MMP-9 mRNA maksimalna (6-60-kratno) v 16 do 24 urah in seje povrnila skoraj na osnovno linijo v 48 do 72 urah. MMP-2 mRNA je bil ugotovljiv, vendar le 1,6-krat povišan 24 ur po obsevanju. Časovni poteki za indukcijo MMP-1 in MMP-9 proteinov in aktivnosti z 2 MED UVB so ustrezali tistim, opazovanim za njihove mRNA. Induciran m bil niti MMP-2 protein niti aktivnost.
Z Northern analizo UVB-obdelane kože z MMP-3 (stromelizin I)-specifično sondo smo dobili rezultate, identične tistim, ki smo jih dobili s sondo MMP-3 popolne dolžine (sl. 2b), medtem ko hibridizacija z MMP-10 (stromelizin II)-specifično sondo ni dala signala. To kaže, da izmed stromelizinov inducira UVB pretežno stromelizin I.
Indukcija MMP z nizko dozo UVB
Osebke smo izpostavljali UVB dozam v območju od 0,01 do 2 MED, kot je opisano zgoraj. Vzorce kože s popolno debelino (6 mm valji) smo dobili 24 ur po obsevanju z obdelanih in neobdelanih mest. Vzorce smo homogenizirali v 20 mM Tris HC1 (pH 7,6), 5 mM CaCl2 in centrifugirali 10 minut pri 3000xg. Supematante smo uporabili za merjenje MMP-1 in MMP-9 proteinov z Westem blot-om (100 gg/progo) ob uporabi kemilumimscenčne detekcije in aktivnosti s hidrolizo Ή fibrilamega kolagena (100 pLg/test) v skladu s Hu, C.L. et al., Anal Biochem (1978) 88:638-643) oz. želatinsko cimografijo (20 ^ig/test) v skladu s Hibbs, M.S. et al., J Biol Chem (1985) 260:24939
2500. Uporabljena MMP-1 in MMP-9 protitelesa so opisana v Werb, Z. et al., J Celi Biol (1989) 109:877-889, oz. Murphy, G. et al., Biochem J (1989) 258:463-472. Rezultati teh testov so prikazani na sl. 3a in 3b.
Na sl. 3a so MMP-1 proteinske vrednosti prikazane z odprtimi stolpiči, medtem ko so MMP-1 aktivnostne vrednosti prikazane s šrafiranimi stolpiči. Vložek na sl. 3a kaže v
reprezentativne Westem Blote z dveh osebkov. Širši 54 KDa trak je intakten MMP-1 in manjši 45 KDa trak je proteolitsko predelana aktivirana oblika MMP-1.
Na sl. 3b so prikazane MMP-9 proteinske vrednosti z odprtimi stolpiči, kjer so MMP9 aktivnostne vrednosti prikazane s šrafiranimi stolpiči. Vložek na sl. 3b prikazuje reprezentativen Westem Blot (leva ploskev) in reprezentativen cimogram (desna ploskev). Večkratni trakovi na cimogramu so proteolitsko predelane aktivne oblike MMP-9.
Intenzitete trakov smo kvantificirali z lasersko denzitometrijo. Rezultati so podani kot povprečje ± SEM od n=10.
Kot je prikazano na sl. 3a in 3b, je bila indukcija MMP-1 in MMP-9 proteinov in aktivnosti odvisna od doze in za oba MMP so se spremembe v proteinu in aktivnosti zrcalile druga v drugi. MMP-1 je bil induciran z vsemi dozami testirane UVB, medtem ko je bil MMP-9 induciran z dozami > 0,1 MED. Indukcija je bila maksimalna pri eni (1) MED in približno polovično maksimalna pri 0,1 MED. 0,1 MED UVB je ekvivalentna dvem do trem minutam sončenja poletnega dne, ki ne povzroči zaznavne kožne pordečitve.
Indukcija AP-1 in NF-KB z nizko dozo UVB
Osebke smo obsevali in vzorce tkiva vzeli, kot je opisano zgoraj. Nuklearne ekstrakte smo pripravili iz vzorcev, kot je opisano v Fisher, G. J. et al., J Biol Chem (1994) 269:20629-20635. Biopsije (pribl. 200 mg mokre mase), ki so vsebovale ~108 celic, so dale povprečno 500 pg nuklearnega ekstraktnega proteina. Teste premika elektroforetske mobilnosti (8 pg nuklearnega ekstraktnega proteina) smo izvedli ob uporabi 32P-markiranih DNA sond, ki vsebujejo AP-1 in NF-KB konsenzus in mutirane DNA-vezavne sekvence, kot je opisano v Fisher, G. J. et al., zgoraj. Protitelesa za superpremike smo dobili od Santa Cruz Biotechnology. Jun in fos protitelesa so imela široko reaktivnost za vse jun oz. fos družinske člane. NF-KB protitelo je bilo specifično za p65/Rel A. Rezultati teh testov so prikazani na sl. 4a, 4b, 4c in 4d (NS označuje nespecifične primere). Vložki za te slike prikazujejo reprezentativne AP-1 in NF-KB retardirane komplekse. +Compet označuje dodatek 100-kratnega prebitka nemarkirane sonde; Mut označuje mutirano P sondo.
Sl. 4a prikazuje AP-1 in NF-KB vezavo v neobsevani in obsevani (4 ure po 2 MED UVB) koži. Kot je prikazano na sl. 4a, je bila vezava obeh transkripcijskih faktorjev na njihove DNA odzivne elemente specifična, kot je prikazano z izgubo retardiranih kompleksov z mutiranimi markiranimi sondami. Protitelesih superpremiki so pokazali, da so specifični AP-1 in NF-KB retardirani kompleksi, opazovani z ekstraktom iz UVB-obsevane kože, vsebovali jun in fos proteine oz. Rel A protein.
Sl. 4b in 4c prikazujeta časovne poteke indukcije AP-1 oz. NF-KB DNA vezave z 2 MED OVB. Opisani rezultati so povprečje ± SEM, n=9. Kot je prikazano, je prišlo do indukcije obeh faktorjev po 15 minutah.
Sl. 4d prikazuje odvisnost indukcije AP-1 (predstavljeno z odprtimi stolpiči) in NF-KB (predstavljeno s šrafiranimi stolpiči) od doze. DNA vezavo merimo 30 minut po obsevanju. Kot je prikazano, seje polovična maksimalna indukcija obeh faktorjev pojavila pri približno 0,1 MED in maksimalna indukcija pri ena (1) MED. Odvisnosti od UVB doze za indukcijo teh faktorjev so se tesno ujemale s tistimi, opisanimi zgoraj za indukcijo MMP-1 in MMP-9, skladno z udeležbo teh transkripcijskih faktorjev v UVB-induciranih povečanjih v teh dveh MMP.
Inhibicija UVB indukcije AP-1, MMP-1 in MMP-9
0,1% all-trans retinojske kisline (t.RA) in njen nosilec (70% etanola in 30% propilen glikola) ali 0,05% glukokortikoid (GC) klobetazol propionata in njegov nosilec (2% propilenglikol + 2% sorbitan seskvioleat v alvolenu) smo aplicirali (300 mg formulacije/6 cm2 kože) osebkom 48 ur, kot je opisano v Fisher, G. J. et al, J Invest Dermatol (1991) 96:699-707. Obdelana mesta na koži smo nato obsevali z 2 MED UVB. Kožo smo dobili, kot je opisano zgoraj, 30 minut po izpostavljanju AP-1 meritvam ali 24 ur po izpostavljanju MMP meritvam. AP-1 meritve ter MMP-1 in MMP-9 meritve smo izvedli, kot je opisano zgoraj. Za določitev, če je t-RA spremenil UVB-inducirano kožno pordečitev, smo osebke obdelovali z 0,1% t-RA in njenim nosilcem 24 ur. Obdelane površine smo obsevali z 10-80 mJ/cm2 UVB in določili pordečitev kože 24 ur zatem z Minolta kromametrom. Rezultati teh testov so prikazani na sl. 5a, 5b, 5c, 5d in 5e.
Sl. 5a prikazuje AP-1 meritve. Kot je prikazano, je predhodna obdelava kože s t-RA zmanjšala UVB-inducirano AP-1 DNA vezavo za približno 70%.
Sl. 5b in 5c prikazujeta MMP-1 in MMP-9 meritve. Kot je prikazano, je predhodna tRA obdelava zmanjšala UVB-inducirane MMP-1 in MMP-9 mRNA, proteine in aktivnosti 50%-80%.
Sl. 5d prikazuje teste na učinek predhodne t-RA obdelave na pordečitev kože. Kot je prikazano, čeprav t-RA absorpcija prekriva UVB območje (t-RA Xmaks = 351 nm), tRA ni zmanjšala UVB-inducirane pordečitve kože. To kaže na to, da so bila opazovana zmanjšanja v EP-1 in MMP indukciji specifična, ne pa zaradi absorpcije UVB s t-RA.
Sl. 5e prikazuje učinke predhodne obdelave kože z GC. Kot je prikazano, je predhodna GC obdelava zmanjšala MMP-1 in MMP-9 aktivnosti do obsegov, ki so podobni tistim, opazovanim iz predhodnih t-RA obdelav.
Publikacije, na katere smo se sklicevali v gornjem opisu, so s tem izrecno vključene kot referenca.
Claims (18)
- PATENTNI ZAHTEVKI1. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo retinoida in hidroksamata v dermatološko primernem nosilcu za lokalno uporabo.
- 2. Sestavek po zahtevku 1, označen s tem, daje retinoid all-trans retinojska kislina, 13-cis retinojska kislina, retinol, retinal ali njihova zmes.
- 3. Sestavek po zahtevku 1, označen s tem, daje hidroksamat galardin, batimastat, marimastat ah njihova zmes.
- 4. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo retinoida in famezil transferaznega inhibitorja v dermatološko primernem nosilcu za lokalno uporabo.
- 5. Sestavek po zahtevku 4, označen s tem, da je retinoid all-trans retinojska kislina, 13-cis retinojska kislina, retinol, retinal ali njihova zmes.
- 6. Sestavek po zahtevku 4, označen s tem, daje famezil transferazni inhibitor B581, famezil acetat, α-hidroksifamezilfosforjeva kislina ali njihova zmes.
- 7. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo retinoida in glukokortikoida v dermatološko primernem nosilcu za lokalno uporabo.
- 8. Sestavek po zahtevku 7, označen s tem, da je retinoid all-trans retinojska kislina, 13-cis retinojska kislina, retinol, retinal ali njihova zmes.p:\pr26552jun
- 9. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo retinoida in vitamina D3 v dermatološko primernem nosilcu za lokalno uporabo.
- 10. Sestavek po zahtevku 9, označen s tem, da je retinoid all-trans retinojska kislina, 13-cis retinojska kislina, retinol, retinal ali njihova zmes.
- 11. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo vitamina D3 in hidroksamata v dermatološko primernem nosilcu za lokalno uporabo.
- 12. Sestavek po zahtevku 11, označen s tem, da je retinoid all-trans retinojska kislina, 13-cis retinojska kislina, retinol, retinal ali njihova zmes.
- 13. Sestavek po zahtevku 11, označen s tem, da je hidroksamat galardin, batimastat, marimastat ali njihova zmes.
- 14. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo vitamina D3 in famezil transferaznega inhibitorja v dermatološko primernem nosilcu za lokalno uporabo.
- 15. Sestavek po zahtevku 14, označen s tem, da je famezil transferazni inhibitor B581, famezil acetat, α-hidroksifamezil fosforjeva kislina ali njihova zmes.
- 16. Farmacevtski sestavek za preprečevanje staranja od svetlobe nepoškodovane kože zaradi vpliva svetlobe, označen s tem, da vsebuje kombinacijo glukokortikoida in hidroksamata v dermatološko primernem nosilcu za lokalno uporabo.
- 17. Sestavek po zahtevku 16, označen s tem, da je hidroksamat galardin, batimastat, marimastat ali njihova zmes.p:\pr26552jun
- 18. Uporaba inhibitorja z ultravijoličnim B-sevanjem inducibilne matrične metaloproteinaze za pripravo zdravila za preprečevanje staranja nepoškodovane človeške kože zaradi vpliva svetlobe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/588,771 US5837224A (en) | 1996-01-19 | 1996-01-19 | Method of inhibiting photoaging of skin |
PCT/US1997/000791 WO1997025969A1 (en) | 1996-01-19 | 1997-01-17 | Method of inhibiting photoaging of skin |
Publications (1)
Publication Number | Publication Date |
---|---|
SI9720015A true SI9720015A (sl) | 1999-10-31 |
Family
ID=24355242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9720015A SI9720015A (sl) | 1996-01-19 | 1997-01-17 | Postopek za preprečevanje staranja kože zaradi vpliva svetlobe |
Country Status (21)
Country | Link |
---|---|
US (1) | US5837224A (sl) |
EP (1) | EP0883398A4 (sl) |
JP (1) | JP3705820B2 (sl) |
CN (1) | CN1086937C (sl) |
AR (1) | AR005650A1 (sl) |
BR (1) | BR9707018A (sl) |
CA (1) | CA2241981C (sl) |
CO (1) | CO4770951A1 (sl) |
CZ (1) | CZ291530B6 (sl) |
EE (1) | EE9800216A (sl) |
HK (1) | HK1018885A1 (sl) |
HU (1) | HUP9900655A3 (sl) |
LT (1) | LT4515B (sl) |
MY (1) | MY119711A (sl) |
NO (1) | NO983019L (sl) |
NZ (1) | NZ330860A (sl) |
PL (1) | PL327827A1 (sl) |
SI (1) | SI9720015A (sl) |
SK (1) | SK95998A3 (sl) |
TR (1) | TR199801376T2 (sl) |
WO (1) | WO1997025969A1 (sl) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528483B2 (en) | 1995-06-07 | 2003-03-04 | André Beaulieu | Method of producing concentrated non-buffered solutions of fibronectin |
TR199800990T2 (xx) * | 1995-12-08 | 1998-07-21 | Agouron Pharmaceuticals, Inc. | Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler. |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
WO1998036742A1 (en) * | 1997-02-25 | 1998-08-27 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US20050058709A1 (en) * | 1997-06-04 | 2005-03-17 | Fisher Gary J. | Methods for inhibiting photoaging of human skin using orally-administered agent |
JP3973748B2 (ja) * | 1998-01-14 | 2007-09-12 | 花王株式会社 | 発毛抑制剤 |
US6683069B1 (en) * | 1998-04-02 | 2004-01-27 | Regents Of The University Of Michigan | Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin |
FR2777183B1 (fr) * | 1998-04-10 | 2001-03-02 | Oreal | Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant |
FR2777186B1 (fr) * | 1998-04-10 | 2001-03-09 | Oreal | Utilisation d'au moins un hydroxystilbene dans une composition raffermissante |
US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6071955A (en) * | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
WO2000051562A1 (en) * | 1999-03-03 | 2000-09-08 | Shiseido Company, Ltd. | Matrix metalloprotease inhibitor and utilization thereof |
WO2000059900A1 (en) * | 1999-04-01 | 2000-10-12 | The Board Of Trustees Of The University Of Arkansas | P38mapk inhibitor and uses thereof |
US7268148B2 (en) * | 1999-05-20 | 2007-09-11 | Regents Of The University Of Michigan | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
US20040235950A1 (en) * | 1999-05-20 | 2004-11-25 | Voorhees John J. | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
CA2378829A1 (en) * | 1999-07-20 | 2001-01-25 | Merck & Co., Inc. | Sustained release drug dispersion delivery device |
US6982284B1 (en) | 1999-09-10 | 2006-01-03 | Applied Genetics Incorporated Dermatics | Compositions and methods for modification of skin lipid content |
DE19955349A1 (de) * | 1999-11-17 | 2001-08-02 | Switch Biotech Ag | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
JP4074043B2 (ja) * | 2000-03-27 | 2008-04-09 | 株式会社資生堂 | 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法 |
DE10020447A1 (de) * | 2000-03-31 | 2001-10-11 | Henkel Kgaa | Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie |
US20020012641A1 (en) * | 2000-06-26 | 2002-01-31 | Voorhees John J. | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin |
WO2002019982A2 (en) * | 2000-06-29 | 2002-03-14 | Quick Med Technologies, Inc. | Cosmetic composition and method for reducing or preventing wrinkling |
US20040185127A1 (en) * | 2001-06-29 | 2004-09-23 | Lerner David S. | Cosmetic composition and method |
EP1296638A2 (en) | 2000-07-06 | 2003-04-02 | The Regents Of The University Of Michigan | UVA (>360-400) AND UVB (300-325) SPECIFIC SUNSCREENS |
FR2811561B1 (fr) * | 2000-07-13 | 2003-03-21 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase |
FR2811563B1 (fr) * | 2000-07-13 | 2003-06-20 | Oreal | Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive, et au moins un compose augmentant la synthese des glycosaminoglycanes |
US20020119107A1 (en) * | 2000-12-18 | 2002-08-29 | James Varani | Method for protecting and restoring skin using selective MMP inhibitors |
DE10102784A1 (de) * | 2001-01-22 | 2002-08-01 | Henkel Kgaa | Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
JP2002277455A (ja) * | 2001-03-15 | 2002-09-25 | Shiseido Co Ltd | 皮膚老化因子検出組成物及び検出方法 |
MXPA04008722A (es) | 2002-03-08 | 2005-07-13 | Eisai Co Ltd | Compuestos macrociclicos utiles como farmaceuticos. |
US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
WO2003090688A2 (en) * | 2002-04-24 | 2003-11-06 | Van Andel Research Institute | Enhancement of human epidermal melanogenesis |
JP5122060B2 (ja) * | 2002-06-25 | 2013-01-16 | 株式会社 資生堂 | 抗老化剤 |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
CN101845009B (zh) | 2002-07-29 | 2012-10-03 | 卡达克斯药物公司 | 用于抑制和改善疾病的类胡萝卜素结构类似物 |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US7521584B2 (en) * | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US20050143475A1 (en) * | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
EP1617777A4 (en) | 2003-04-10 | 2010-11-03 | Gentlewaves Llc | PHOTOMODULATION METHODS AND DEVICES FOR REGULATING CELL PROLIFERATION AND GENE EXPRESSION |
WO2005011606A2 (en) | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
FR2858932B1 (fr) * | 2003-08-22 | 2009-10-30 | Oreal | Composition destinee a lutter contre la degradation des fibres de collagene induite en condition d'exposition solaire naturelle |
US20050058611A1 (en) * | 2003-08-22 | 2005-03-17 | L'oreal | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight |
EP1730522A2 (en) * | 2004-03-29 | 2006-12-13 | Howard Murad | Methods for treating dermatological conditions in a patient |
EP1750723A1 (en) * | 2004-04-14 | 2007-02-14 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
US20060265030A1 (en) * | 2004-11-12 | 2006-11-23 | Light Bioscience, Llc | System and method for photodynamic cell therapy |
WO2006071456A2 (en) * | 2004-12-02 | 2006-07-06 | The University Of North Carolina At Chapel Hill | Inhibition of hsp27 phosphorylation for treatment of blistering disorders |
WO2007064871A2 (en) * | 2005-12-02 | 2007-06-07 | Howard Murad | Diagnostic and treatment regimen for achieving body water homeostasis |
US7642402B2 (en) * | 2005-12-20 | 2010-01-05 | Kao Corporation | Human photoaged skin model |
US8771647B2 (en) * | 2005-12-20 | 2014-07-08 | Kao Corporation | Human photoaged skin model |
WO2007134219A2 (en) * | 2006-05-11 | 2007-11-22 | Living Proof, Inc. | In situ polymerization for skin treatment |
KR100879558B1 (ko) * | 2007-07-31 | 2009-01-22 | 라이브켐 주식회사 | 디벤조파라디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제 |
WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
CN102014859B (zh) * | 2008-04-22 | 2015-05-20 | 法国国家科学研究中心 | 抑制黑素生成的新组合物及其应用 |
US8609075B2 (en) | 2009-09-30 | 2013-12-17 | Shiseido Company, Ltd. | Heparanase activity inhibitor |
CN102573819A (zh) | 2009-09-30 | 2012-07-11 | 株式会社资生堂 | 乙酰肝素酶活性抑制剂以及含有该乙酰肝素酶活性抑制剂的皱纹改善剂和药物组合物 |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
US10267796B2 (en) * | 2010-10-25 | 2019-04-23 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
EP2934555B1 (en) | 2012-12-21 | 2021-09-22 | Astellas Institute for Regenerative Medicine | Methods for production of platelets from pluripotent stem cells |
JP2015221768A (ja) * | 2014-05-23 | 2015-12-10 | 日本メナード化粧品株式会社 | 皮膚外用剤または内用剤 |
JP2016216435A (ja) * | 2015-05-18 | 2016-12-22 | 共栄化学工業株式会社 | 評価方法 |
JP6157659B1 (ja) * | 2016-02-10 | 2017-07-05 | イノレックス インベストメント コーポレイション | 紫外線誘発性脂質過酸化を低減する相乗的組成物、配合物及び関連の方法 |
US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
CN112263529A (zh) * | 2020-10-27 | 2021-01-26 | 圣菲之美(湖北)生物科技有限公司 | 一种抗衰老组合物及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4877805A (en) * | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
US4603146A (en) * | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
US5019569A (en) * | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
EP0357646B1 (en) * | 1987-04-06 | 1995-03-22 | Daltex Medical Sciences, Inc. | Treatment of aged skin with oral 13-cis-retinoic acid |
US4994491A (en) * | 1988-12-14 | 1991-02-19 | Molecular Design International | Dermal uses of trans-retinoids for the treatment of cancer |
MY106263A (en) * | 1989-01-19 | 1995-04-29 | Ortho Pharma Corp | Method for the treatment or prevention of intrinsically aged skin with retinoids |
US5002760A (en) * | 1989-10-02 | 1991-03-26 | Katzev Phillip K | Retinol skin care composition |
US5051449A (en) * | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
WO1993010755A1 (en) * | 1991-11-25 | 1993-06-10 | Richardson-Vicks, Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
GR1002207B (en) * | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
JPH10513452A (ja) * | 1995-02-03 | 1998-12-22 | コスメダーム・テクノロジーズ | 皮膚刺激を軽減するための製剤及び方法 |
JP2002515851A (ja) * | 1995-06-08 | 2002-05-28 | ジヨンソン・アンド・ジヨンソン・コンシユーマー・カンパニーズ・インコーポレーテツド | 日光遮蔽組成物 |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
-
1996
- 1996-01-19 US US08/588,771 patent/US5837224A/en not_active Expired - Lifetime
-
1997
- 1997-01-17 CZ CZ19982258A patent/CZ291530B6/cs not_active IP Right Cessation
- 1997-01-17 EE EE9800216A patent/EE9800216A/xx unknown
- 1997-01-17 WO PCT/US1997/000791 patent/WO1997025969A1/en active IP Right Grant
- 1997-01-17 CA CA002241981A patent/CA2241981C/en not_active Expired - Lifetime
- 1997-01-17 HU HU9900655A patent/HUP9900655A3/hu unknown
- 1997-01-17 BR BR9707018A patent/BR9707018A/pt not_active IP Right Cessation
- 1997-01-17 EP EP97903847A patent/EP0883398A4/en not_active Withdrawn
- 1997-01-17 MY MYPI97000167A patent/MY119711A/en unknown
- 1997-01-17 JP JP52622497A patent/JP3705820B2/ja not_active Expired - Fee Related
- 1997-01-17 AR ARP970100191A patent/AR005650A1/es unknown
- 1997-01-17 SI SI9720015A patent/SI9720015A/sl unknown
- 1997-01-17 CN CN97191735A patent/CN1086937C/zh not_active Expired - Fee Related
- 1997-01-17 SK SK959-98A patent/SK95998A3/sk unknown
- 1997-01-17 PL PL97327827A patent/PL327827A1/xx unknown
- 1997-01-17 NZ NZ330860A patent/NZ330860A/xx not_active IP Right Cessation
- 1997-01-17 CO CO97001933A patent/CO4770951A1/es unknown
- 1997-01-17 TR TR1998/01376T patent/TR199801376T2/xx unknown
-
1998
- 1998-06-29 NO NO983019A patent/NO983019L/no not_active Application Discontinuation
- 1998-07-09 LT LT98-091A patent/LT4515B/lt not_active IP Right Cessation
-
1999
- 1999-09-14 HK HK99103976A patent/HK1018885A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CO4770951A1 (es) | 1999-04-30 |
CA2241981C (en) | 2002-03-19 |
US5837224A (en) | 1998-11-17 |
LT98091A (en) | 1999-02-25 |
HUP9900655A1 (hu) | 1999-07-28 |
CA2241981A1 (en) | 1997-07-24 |
NO983019L (no) | 1998-08-19 |
HK1018885A1 (en) | 2000-01-07 |
AU1831797A (en) | 1997-08-11 |
EP0883398A4 (en) | 1999-05-12 |
AR005650A1 (es) | 1999-07-14 |
JP3705820B2 (ja) | 2005-10-12 |
EE9800216A (et) | 1999-04-15 |
MY119711A (en) | 2005-07-29 |
LT4515B (lt) | 1999-06-25 |
JP2000503660A (ja) | 2000-03-28 |
NO983019D0 (no) | 1998-06-29 |
NZ330860A (en) | 1999-11-29 |
AU701132B2 (en) | 1999-01-21 |
BR9707018A (pt) | 1999-07-20 |
CZ225898A3 (cs) | 1998-10-14 |
WO1997025969A1 (en) | 1997-07-24 |
HUP9900655A3 (en) | 2000-09-28 |
EP0883398A1 (en) | 1998-12-16 |
CN1086937C (zh) | 2002-07-03 |
CN1211178A (zh) | 1999-03-17 |
SK95998A3 (en) | 1999-01-11 |
CZ291530B6 (cs) | 2003-03-12 |
TR199801376T2 (xx) | 1998-10-21 |
PL327827A1 (en) | 1999-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9720015A (sl) | Postopek za preprečevanje staranja kože zaradi vpliva svetlobe | |
Zouboulis et al. | Aesthetic aspects of skin aging, prevention, and local treatment | |
Rabe et al. | Photoaging: mechanisms and repair | |
US6630516B2 (en) | Methods and compositions for preventing and treating chronological aging in human skin | |
US6337320B1 (en) | Reparatives for ultraviolet radiation skin damage | |
EP0750512B1 (en) | A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction | |
Lin et al. | Modulation of microphthalmia-associated transcription factor gene expression alters skin pigmentation | |
Arbab et al. | Review on skin whitening agents | |
AU701132C (en) | Method of inhibiting photoaging of skin | |
KR100352687B1 (ko) | 광노화를예방하기위한화장품 | |
Welsh et al. | Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice | |
Ghersetich et al. | Receptors in skin ageing and antiageing agents | |
JPH01305025A (ja) | 色素沈着抑制剤 | |
Alberts et al. | Developing topical prodrugs for skin cancer prevention | |
Humbert et al. | The Action of Vitamin C for Treating Wrinkles and Protecting Skin from Photodamage. | |
Duarte et al. | Vitamin C, gene expression and skin health | |
JPH08217659A (ja) | メラニンの脱色方法 | |
Hamayun et al. | Comparison of the efficacy and safety of topical 4% hydroquinone cream vs topical 10% glutathione plus 5% ascorbic acid cream in patients with epidermal melasma | |
Westerhof et al. | Bleaching agents | |
Burke et al. | Topical Vitamins E, C, and Ferulic Acid and Topical L-Selenomethionine | |
Rittié et al. | Anti-aging effects of retinoids and mechanisms of action | |
Pozzo et al. | Topical Agents for Melasma: A Perspective on Therapeutic Approaches and Their Molecular Bases | |
KR20030092204A (ko) | 프럭토스 1,6-디포스페이트 또는 그 유도체를 함유한미백용 피부외용제 조성물 | |
Loy et al. | Biology of skin pigmentation and cosmetic skin color control | |
MXPA99007883A (es) | Metodos y composiciones para prevernir y tratar el envejecimiento cronológico en la piel humana |